Skip to main content
SpringerLink
Log in

Current Management of Retinoblastoma

  • Living reference work entry
  • First Online:
Albert and Jakobiec's Principles and Practice of Ophthalmology

  • 52 Accesses

Abstract

Management of retinoblastoma is evolving and treatment algorithms have been changing rapidly over the past few decades. The prognosis for survival and visual function has improved substantially over the past century. Today, therapies are divided into whole eye and focal tumor treatment methods. Whole eye treatment methods include chemotherapy, enucleation, and external beam radiation. Localized treatment methods include thermotherapy, cryotherapy, laser photocoagulation, and plaque radiotherapy. Over the past two decades, the advent of chemotherapeutic treatment options has dramatically changed the management of retinoblastoma, causing a marked shift in treatment strategies and outcomes toward globe preserving therapies. Treatment planning are increasingly being provided by a multidisciplinary team, including pediatric ophthalmologists, geneticists, pediatric oncologists, radiation oncologists, oncology nurses, and social workers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997;278(15):1262–7.

    Article  CAS  PubMed  Google Scholar 

  2. Abramson DH, Niksarli K, Ellsworth RM, Servodidio CA. Changing trends in the management of retinoblastoma: 1951-1965 vs 1966-1980. J Pediatr Ophthalmol Strabismus. 1994;31(1):32–7.

    Article  CAS  PubMed  Google Scholar 

  3. Singh AD, Shields CL, Shields JA. Prognostic factors in retinoblastoma. J Pediatr Ophthalmol Strabismus. 2000;37(3):134–41. quiz 68–9

    Article  CAS  PubMed  Google Scholar 

  4. Ajaiyeoba IA, Akang EE, Campbell OB, Olurin IO, Aghadiuno PU. Retinoblastomas in Ibadan: treatment and prognosis. West Afr J Med. 1993;12(4):223–7.

    CAS  PubMed  Google Scholar 

  5. Shields CL, Lally SE, Leahey AM, et al. Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Curr Opin Ophthalmol. 2014;25(5):374–85.

    Article  PubMed  Google Scholar 

  6. Shields CL, Kaliki S, Rojanaporn D, Al-Dahmash S, Bianciotto CG, Shields JA. Intravenous and intra-arterial chemotherapy for retinoblastoma: what have we learned? Curr Opin Ophthalmol. 2012;23(3):202–9.

    Article  PubMed  Google Scholar 

  7. Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010;21(3):203–12.

    Article  PubMed  Google Scholar 

  8. Chawla B, Jain A, Azad R. Conservative treatment modalities in retinoblastoma. Indian J Ophthalmol. 2013;61(9):479–85.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Shields CL, Fulco EM, Arias JD, et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye (Lond). 2013;27(2):253–64.

    Article  CAS  Google Scholar 

  10. Shields CL, Mashayekhi A, Au AK, et al. The international classification of retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113(12):2276–80.

    Article  PubMed  Google Scholar 

  11. Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol. 1996;114(11):1321–8.

    Article  CAS  PubMed  Google Scholar 

  12. Beck MN, Balmer A, Dessing C, Pica A, Munier F. First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol. 2000;18(15):2881–7.

    Article  CAS  PubMed  Google Scholar 

  13. Eckstein LA, Van Quill KR, Bui SK, Uusitalo MS, O'Brien JM. Cyclosporin a inhibits calcineurin/nuclear factor of activated T-cells signaling and induces apoptosis in retinoblastoma cells. Invest Ophthalmol Vis Sci. 2005;46(3):782–90.

    Article  PubMed  Google Scholar 

  14. Shields JA, Shields CL, Meadows AT. Chemoreduction in the management of retinoblastoma. Am J Ophthalmol. 2005;140(3):505–6.

    Article  PubMed  Google Scholar 

  15. Wilson MW, Haik BG, Liu T, Merchant TE, Rodriguez-Galindo C. Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma. Am J Ophthalmol. 2005;140(3):397–406.

    Article  CAS  PubMed  Google Scholar 

  16. Zage PE, Reitman AJ, Seshadri R, et al. Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma. Pediatr Blood Cancer. 2008;50(3):567–72.

    Article  PubMed  Google Scholar 

  17. Wilson MW, Rodriguez-Galindo C, Haik BG, Moshfeghi DM, Merchant TE, Pratt CB. Multiagent chemotherapy as neoadjuvant treatment for multifocal intraocular retinoblastoma. Ophthalmology. 2001;108(11):2106–14. discussion 14-5

    Article  CAS  PubMed  Google Scholar 

  18. Shields CL, Mashayekhi A, Cater J, Shelil A, Meadows AT, Shields JA. Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors. Trans Am Ophthalmol Soc. 2004;102:35–44. discussion 44–5

    Google Scholar 

  19. Reese AB, Hyman GA, Merriam GR Jr, Forrest AW, Kligerman MM. Treatment of retinoblastoma by radiation and triethylenemelamine. AMA Arch Ophthalmol. 1954;53(4):505–13.

    Article  CAS  PubMed  Google Scholar 

  20. Francis JHAD. Recent advances in retinoblastoma treatment. Cham: Springer; 2015.

    Book  Google Scholar 

  21. Mohri M. The development of a new system of selective ophthalmic arterial infusion for the patients of intraocular retinoblastoma (in Japanese). Keio Igaku (J Keio Med Soc). 1993;70:679–87.

    Google Scholar 

  22. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol. 2004;9(2):69–73.

    Article  PubMed  Google Scholar 

  23. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115(8):1398–404. 1404.e1

    Article  PubMed  Google Scholar 

  24. Area C, Yen CJ, Chevez-Barrios P, et al. Technical and anatomical factors affecting intra-arterial chemotherapy fluoroscopy time and radiation dose for intraocular retinoblastoma. J Neurointerv Surg. 2019;11(12):1273–76.

    Google Scholar 

  25. Vijayakrishnan R, Shields CL, Ramasubramanian A, Emrich J, Rosenwasser R, Shields JA. Irradiation toxic effects during intra-arterial chemotherapy for retinoblastoma: should we be concerned? Arch Ophthalmol. 2010;128(11):1427–31.

    Article  PubMed  Google Scholar 

  26. Gobin YP, Rosenstein LM, Marr BP, Brodie SE, Abramson DH. Radiation exposure during intra-arterial chemotherapy for retinoblastoma. Arch Ophthalmol. 2012;130(3):403–4. author reply 404–5

    Google Scholar 

  27. Thampi S, Hetts SW, Cooke DL, et al. Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution. Clin Ophthalmol. 2013;7:981–9.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011;129(6):732–7.

    Article  PubMed  Google Scholar 

  29. Shields CL, Manjandavida FP, Lally SE, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014;121(7):1453–60.

    Article  PubMed  Google Scholar 

  30. Jabbour P, Chalouhi N, Tjoumakaris S, et al. Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma. J Neurosurg Pediatr. 2012;10(3):175–81.

    Article  PubMed  Google Scholar 

  31. Choi S, Han JW, Kim H, et al. Combined chemotherapy and intra-arterial chemotherapy of retinoblastoma. Korean J Pediatr. 2013;56(6):254–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology. 2010;117(8):1623–9.

    Article  PubMed  Google Scholar 

  33. Abramson DH, Francis JH, Dunkel IJ, Marr BP, Brodie SE, Gobin YP. Ophthalmic artery chemosurgery for retinoblastoma prevents new intraocular tumors. Ophthalmology. 2013;120(3):560–5.

    Article  PubMed  Google Scholar 

  34. Abramson DH, Marr BP, Dunkel IJ, et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol. 2012;96(4):499–502.

    Article  PubMed  Google Scholar 

  35. Palioura S, Gobin YP, Brodie SE, Marr BP, Dunkel IJ, Abramson DH. Ophthalmic artery chemosurgery for the management of retinoblastoma in eyes with extensive (>50%) retinal detachment. Pediatr Blood Cancer. 2012;59(5):859–64.

    Article  PubMed  Google Scholar 

  36. Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: report no. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol. 2011;129(11):1399–406.

    Article  PubMed  Google Scholar 

  37. Francis JH, Roosipu N, Levin AM, et al. Current treatment of bilateral retinoblastoma: the impact of intraarterial and intravitreous chemotherapy. Neoplasia. 2018;20(8):757–63.

    Google Scholar 

  38. Ravindran K, Dalvin LA, Pulido JS, Brinjikji W. Intra-arterial chemotherapy for retinoblastoma: an updated systematic review and meta-analysis. J Neurointerv Surg. 2019;11(12):1266–72.

    Google Scholar 

  39. Dalvin LA, Ancona-Lezama D, Lucio-Alvarez JA, Masoomian B, Jabbour P, Shields CL. Ophthalmic vascular events after primary unilateral intra-arterial chemotherapy for retinoblastoma in early and recent eras. Ophthalmology. 2018;125(11):1803–11.

    Article  PubMed  Google Scholar 

  40. Yousef YA, Soliman SE, Astudillo PPP, et al. Intra-arterial chemotherapy for retinoblastoma: a systematic review. JAMA Ophthalmol. 2016;134(5):584–91.

    Article  PubMed  Google Scholar 

  41. Henkes HE, Manschot WA. The danger of diagnostic biopsy in eyes suspected of an intraocular tumour. Ophthalmologica. 1963;145:467–9.

    Article  CAS  PubMed  Google Scholar 

  42. Abramson DH, Ji X, Francis JH, Catalanotti F, Brodie SE, Habib L. Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds. Br J Ophthalmol. 2019;103(4):488–93.

    Article  PubMed  Google Scholar 

  43. Hwang CK, Aaberg TM Jr, Chevez-Barrios P, et al. Residual intraretinal retinoblastoma after chemoreduction failure. Arch Ophthalmol. 2012;130(2):246–8.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Kivela T, Eskelin S, Paloheimo M. Intravitreal methotrexate for retinoblastoma. Ophthalmology. 2011;118(8):1689. e1–6

    Article  PubMed  Google Scholar 

  45. Ghassemi F, Shields CL, Ghadimi H, Khodabandeh A, Roohipoor R. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma. JAMA Ophthalmol. 2014;132(8):936–41.

    Article  PubMed  CAS  Google Scholar 

  46. Smith SJ, Pulido JS, Salomao DR, Smith BD, Mohney B. Combined intravitreal and subconjunctival carboplatin for retinoblastoma with vitreous seeds. Br J Ophthalmol. 2012;96(8):1073–7.

    Article  PubMed  Google Scholar 

  47. Munier FL, Gaillard MC, Balmer A, Beck-Popovic M. Intravitreal chemotherapy for vitreous seeding in retinoblastoma: recent advances and perspectives. Saudi J Ophthalmol. 2013;27(3):147–50.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Shields CL, Douglass AM, Beggache M, Say EAT, Shields JA. Intravitreous chemotherapy for active vitreous seeding from retinoblastoma: outcomes after 192 consecutive injections. The 2015 Howard Naquin lecture. Retina. 2016;36(6):1184–90.

    Article  CAS  PubMed  Google Scholar 

  49. Francis JH, Schaiquevich P, Buitrago E, et al. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study. Ophthalmology. 2014;121(9):1810–17.

    Article  PubMed  Google Scholar 

  50. Manjandavida FP, Shields CL. The role of intravitreal chemotherapy for retinoblastoma. Indian J Ophthalmol. 2015;63(2):141–5.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Francis JH, Xu XL, Gobin YP, Marr BP, Brodie SE, Abramson DH. Death by water: precautionary water submersion for intravitreal injection of retinoblastoma eyes. Open Ophthalmol J. 2014;8:7–11.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Seregard S, Kock E, Af Trampe E. Intravitreal chemotherapy for recurrent retinoblastoma in an only eye. Br J Ophthalmol. 1995;79(2):194–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Smith SJ, Smith BD. Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2013;97(10):1231–6.

    Article  PubMed  Google Scholar 

  54. Ghassemi F, Shields CL. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 2012;130(10):1268–71.

    Article  PubMed  Google Scholar 

  55. Smith SJ, Smith BD, Mohney BG. Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2014;98(3):292–7.

    Article  PubMed  Google Scholar 

  56. Kiratli H, Koc I, Varan A, Akyuz C. Intravitreal chemotherapy in the management of vitreous disease in retinoblastoma. Eur J Ophthalmol. 2017;27(4):423–7.

    Article  PubMed  Google Scholar 

  57. Mendelsohn ME, Abramson DH, Madden T, Tong W, Tran HT, Dunkel IJ. Intraocular concentrations of chemotherapeutic agents after systemic or local administration. Arch Ophthalmol. 1998;116(9):1209–12.

    Article  CAS  PubMed  Google Scholar 

  58. Hayden BC, Jockovich ME, Murray TG, et al. Pharmacokinetics of systemic versus focal carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma. Invest Ophthalmol Vis Sci. 2004;45(10):3644–9.

    Article  PubMed  Google Scholar 

  59. Mallipatna AC, Dimaras H, Chan HS, Heon E, Gallie BL. Periocular topotecan for intraocular retinoblastoma. Arch Ophthalmol. 2011;129(6):738–45.

    Article  PubMed  Google Scholar 

  60. Kiratli H, Kocabeyoglu S, Bilgic S. Severe pseudo-preseptal cellulitis following sub-Tenon’s carboplatin injection for intraocular retinoblastoma. J AAPOS. 2007;11(4):404–5.

    Article  PubMed  Google Scholar 

  61. Mulvihill A, Budning A, Jay V, et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol. 2003;121(8):1120–4.

    Article  CAS  PubMed  Google Scholar 

  62. Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology. 1999;106(10):1947–50.

    Article  CAS  PubMed  Google Scholar 

  63. Schmack I, Hubbard GB, Kang SJ, Aaberg TM Jr, Grossniklaus HE. Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol. 2006;142(2):310–5.

    Article  CAS  PubMed  Google Scholar 

  64. Chantada GL, Fandino AC, Carcaboso AM, et al. A phase I study of periocular topotecan in children with intraocular retinoblastoma. Invest Ophthalmol Vis Sci. 2009;50(4):1492–6.

    Article  PubMed  Google Scholar 

  65. Simpson AE, Gilbert JA, Rudnick DE, Geroski DH, Aaberg TM Jr, Edelhauser HF. Transscleral diffusion of carboplatin: an in vitro and in vivo study. Arch Ophthalmol. 2002;120(8):1069–74.

    Article  CAS  PubMed  Google Scholar 

  66. Van Quill KR, Dioguardi PK, Tong CT, et al. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology. 2005;112(6):1151–8.

    Article  PubMed  Google Scholar 

  67. Canturk S, Qaddoumi I, Khetan V, et al. Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators. Br J Ophthalmol. 2010;94(11):1432–6.

    Article  CAS  PubMed  Google Scholar 

  68. Jaradat I, Mubiden R, Salem A, Abdel-Rahman F, Al-Ahmad I, Almousa A. High-dose chemotherapy followed by stem cell transplantation in the management of retinoblastoma: a systematic review. Hematol Oncol Stem Cell Ther. 2012;5(2):107–17.

    Article  CAS  PubMed  Google Scholar 

  69. Matsubara H, Makimoto A, Higa T, et al. A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant. 2005;35(8):763–6.

    Article  CAS  PubMed  Google Scholar 

  70. Banna GL, Simonelli M, Santoro A. High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review. Curr Stem Cell Res Ther. 2007;2(1):65–82.

    Article  CAS  PubMed  Google Scholar 

  71. Lee SH, Yoo KH, Sung KW, et al. Tandem high-dose chemotherapy and autologous stem cell rescue in children with bilateral advanced retinoblastoma. Bone Marrow Transplant. 2008;42(6):385–91.

    Article  CAS  PubMed  Google Scholar 

  72. Palma J, Sasso DF, Dufort G, et al. Successful treatment of metastatic retinoblastoma with high-dose chemotherapy and autologous stem cell rescue in South America. Bone Marrow Transplant. 2012;47(4):522–7.

    Article  CAS  PubMed  Google Scholar 

  73. Suzuki S, Kaneko A. Management of intraocular retinoblastoma and ocular prognosis. Int J Clin Oncol. 2004;9(1):1–6.

    Article  PubMed  Google Scholar 

  74. Shields CL, Santos MC, Diniz W, et al. Thermotherapy for retinoblastoma. Arch Ophthalmol. 1999;117(7):885–93.

    Article  CAS  PubMed  Google Scholar 

  75. Shields JA, Shields CL, Parsons H, Giblin ME. The role of photocoagulation in the management of retinoblastoma. Arch Ophthalmol. 1990;108(2):205–8.

    Article  CAS  PubMed  Google Scholar 

  76. Shields JA, Parsons H, Shields CL, Giblin ME. The role of cryotherapy in the management of retinoblastoma. Am J Ophthalmol. 1989;108(3):260–4.

    Article  CAS  PubMed  Google Scholar 

  77. Lincoff H, McLean J, Long R. The cryosurgical treatment of intraocular tumors. Am J Ophthalmol. 1967;63(3):389–99.

    Article  CAS  PubMed  Google Scholar 

  78. Abramson DH, Ellsworth RM, Rozakis GW. Cryotherapy for retinoblastoma. Arch Ophthalmol. 1982;100(8):1253–6.

    Article  CAS  PubMed  Google Scholar 

  79. Abramson DH, Schefler AC. Update on retinoblastoma. Retina. 2004;24(6):828–48.

    Article  PubMed  Google Scholar 

  80. Ellsworth RM. The practical management of retinoblastoma. Trans Am Ophthalmol Soc. 1969;67:462–534.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Truong B, Green AL, Friedrich P, Ribeiro KB, Rodriguez-Galindo C. Ethnic, racial, and socioeconomic disparities in retinoblastoma. JAMA Pediatr. 2015;169(12):1096–104.

    Article  PubMed  Google Scholar 

  82. Rajeshuni N, Whittemore AS, Ludwig CA, Mruthyunjaya P, Moshfeghi DM. Racial, ethnic, and socioeconomic disparities in retinoblastoma enucleation: a population-based study, SEER 18 2000-2014. Am J Ophthalmol. 2020;217:351–2.

    Google Scholar 

  83. Abramson DH, Ellsworth RM. The surgical management of retinoblastoma. Ophthalmic Surg. 1980;11(9):596–8.

    CAS  PubMed  Google Scholar 

  84. Lu JE, Francis JH, Dunkel IJ, et al. Metastases and death rates after primary enucleation of unilateral retinoblastoma in the USA 2007-2017. Br J Ophthalmol. 2018;103(9):1272–7.

    Google Scholar 

  85. Honavar SG, Singh AD. Management of advanced retinoblastoma. Ophthalmol Clin N Am. 2005;18(1):65–73. viii

    Article  Google Scholar 

  86. Kopelman JE, McLean IW, Rosenberg SH. Multivariate analysis of risk factors for metastasis in retinoblastoma treated by enucleation. Ophthalmology. 1987;94(4):371–7.

    Article  CAS  PubMed  Google Scholar 

  87. Uusitalo MS, Van Quill KR, Scott IU, Matthay KK, Murray TG, O'Brien JM. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol. 2001;119(1):41–8.

    CAS  PubMed  Google Scholar 

  88. Schvartzman E, Chantada G, Fandino A, de Davila MT, Raslawski E, Manzitti J. Results of a stage-based protocol for the treatment of retinoblastoma. J Clin Oncol. 1996;14(5):1532–6.

    Article  CAS  PubMed  Google Scholar 

  89. Zelter M, Damel A, Gonzalez G, Schwartz L. A prospective study on the treatment of retinoblastoma in 72 patients. Cancer. 1991;68(8):1685–90.

    Article  CAS  PubMed  Google Scholar 

  90. Namouni F, Doz F, Tanguy ML, et al. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer. 1997;33(14):2368–75.

    Article  CAS  PubMed  Google Scholar 

  91. Chévez-Barrios P, Eagle RC Jr, Krailo M, Piao J, Albert DM, Gao Y, Vemuganti G, Ali MJ, Khetan V, Honavar SG, O'Brien J, Leahey AM, Matthay K, Meadows A, Chintagumpala M. Study of unilateral retinoblastoma with and without histopathologic high-risk features and the role of adjuvant chemotherapy: a Children’s oncology group study. J Clin Oncol. 2019;37(31):2883–91.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Bedford MA, Bedotto C, Macfaul PA. Retinoblastoma. A study of 139 cases. Br J Ophthalmol. 1971;55(1):19–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Shields CL, Shields JA, Cater J, Othmane I, Singh AD, Micaily B. Plaque radiotherapy for retinoblastoma: long-term tumor control and treatment complications in 208 tumors. Ophthalmology. 2001;108(11):2116–21.

    Article  CAS  PubMed  Google Scholar 

  94. Abramson DH, Ellsworth RM, Kitchin FD, Tung G. Second nonocular tumors in retinoblastoma survivors. Are they radiation-induced? Ophthalmology. 1984;91(11):1351–5.

    Article  CAS  PubMed  Google Scholar 

  95. Abramson DH, Beaverson KL, Chang ST, Dunkel IJ, McCormick B. Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma. Arch Ophthalmol. 2004;122(9):1316–23.

    Article  PubMed  Google Scholar 

  96. Brichard B, Heusterspreute M, De Potter P, et al. Unilateral retinoblastoma, lack of familial history and older age does not exclude germline RB1 gene mutation. Eur J Cancer. 2006;42(1):65–72.

    Article  CAS  PubMed  Google Scholar 

  97. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst. 1993;85(14):1121–8.

    Article  CAS  PubMed  Google Scholar 

  98. Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology. 1998;105(4):573–9. discussion 9–80

    Article  CAS  PubMed  Google Scholar 

  99. Foote RL, Garretson BR, Schomberg PJ, Buskirk SJ, Robertson DM, Earle JD. External beam irradiation for retinoblastoma: patterns of failure and dose-response analysis. Int J Radiat Oncol Biol Phys. 1989;16(3):823–30.

    Article  CAS  PubMed  Google Scholar 

  100. Guyer DR, Mukai S, Egan KM, Seddon JM, Walsh SM, Gragoudas ES. Radiation maculopathy after proton beam irradiation for choroidal melanoma. Ophthalmology. 1992;99(8):1278–85.

    Article  CAS  PubMed  Google Scholar 

  101. National Society of Genetic Counselors’ Definition Task F, Resta R, Biesecker BB, et al. A new definition of genetic counseling: National Society of Genetic Counselors’ Task Force report. J Genet Couns 2006; 15(2): 77–83.

    Google Scholar 

  102. Skalet AH, Gombos DS, Gallie BL, et al. Screening children at risk for retinoblastoma: consensus report from the American Association of Ophthalmic Oncologists and Pathologists. Ophthalmology. 2018;125(3):453–8.

    Article  PubMed  Google Scholar 

  103. Richter S, Vandezande K, Chen N, et al. Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am J Hum Genet. 2003;72(2):253–69.

    Article  CAS  PubMed  Google Scholar 

  104. Neriyanuri S, Raman R, Rishi P, Govindasamy K, Ramprasad VL, Sharma T. Prenatal genetic diagnosis of retinoblastoma – clinical correlates on follow-up. Indian J Ophthalmol. 2015;63(9):741–2.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Yahalom C, Macarov M, Lazer-Derbeko G, et al. Preimplantation genetic diagnosis as a strategy to prevent having a child born with an heritable eye disease. Ophthalmic Genet. 2018;39(4):450–6.

    Article  PubMed  Google Scholar 

  106. Price EA, Price K, Kolkiewicz K, et al. Spectrum of RB1 mutations identified in 403 retinoblastoma patients. J Med Genet. 2014;51(3):208–14.

    Article  CAS  PubMed  Google Scholar 

  107. Rushlow D, Piovesan B, Zhang K, et al. Detection of mosaic RB1 mutations in families with retinoblastoma. Hum Mutat. 2009;30(5):842–51.

    Article  CAS  PubMed  Google Scholar 

  108. Rushlow DE, Mol BM, Kennett JY, et al. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol. 2013;14(4):327–34.

    Article  CAS  PubMed  Google Scholar 

  109. McEvoy J, Nagahawatte P, Finkelstein D, et al. RB1 gene inactivation by chromothripsis in human retinoblastoma. Oncotarget. 2014;5(2):438–50.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Wu N, Jia D, Bates B, Basom R, Eberhart CG, MacPherson D. A mouse model of MYCN-driven retinoblastoma reveals MYCN-independent tumor reemergence. J Clin Invest. 2017;127(3):888–98.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Tomar S, Sethi R, Sundar G, Quah TC, Quah BL, Lai PS. Mutation spectrum of RB1 mutations in retinoblastoma cases from Singapore with implications for genetic management and counselling. PLoS One. 2017;12(6):e0178776.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  112. Choy KW, Lee TC, Cheung KF, et al. Clinical implications of promoter hypermethylation in RASSF1A and MGMT in retinoblastoma. Neoplasia. 2005;7(3):200–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Pritchard EM, Dyer MA, Guy RK. Progress in small molecule therapeutics for the treatment of retinoblastoma. Mini Rev Med Chem. 2016;16(6):430–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Lyu X, Wang L, Lu J, Zhang H, Wang L. microRNA485 inhibits the malignant behaviors of retinoblastoma by directly targeting Wnt3a. Oncol Rep. 2019;41(5):3137–47.

    CAS  PubMed  Google Scholar 

  115. Li J, You X. MicroRNA758 inhibits malignant progression of retinoblastoma by directly targeting PAX6. Oncol Rep. 2018;40(3):1777–86.

    CAS  PubMed  Google Scholar 

  116. Delsin LEA, Salomao KB, Pezuk JA, Brassesco MS. Expression profiles and prognostic value of miRNAs in retinoblastoma. J Cancer Res Clin Oncol. 2019;145(1):1–10.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, USA

    Katayoon B. Ebrahimi & Abraham Hang

  2. Department of Ophthalmology, University of Pennsylvania, Scheie Eye Institute, University Of Pennsylvania Health System, Philadelphia, PA, USA

    Joan M. O’Brien

Authors
  1. Katayoon B. Ebrahimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abraham Hang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joan M. O’Brien
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joan M. O’Brien .

Editor information

Editors and Affiliations

  1. Department of Ophthalmology, Oregon Health & Science University Department of Ophthalmology, Portland, OR, USA

    Daniel Albert

  2. Massachusetts Eye and Ear, Boston, MA, USA

    Joan Miller

  3. Department of Ophthalmology, University of Illinois at Chicago Department of Ophthalmology, Chicago, IL, USA

    Dimitri Azar

  4. Department of Ophthalmology, Harvard Medical School, Boston, MA, USA

    Lucy H. Young

Section Editor information

  1. Department of Ophthalmology, Scheie Eye Institute, University of Pennsylania, Philadelphia, USA

    Joan Marie O’Brien

  2. Department of Ophthalmology, Retina Service, Harvard Medical School; Massachusetts Eye and Ear Infirmary, Boston, MA, USA

    Evangelos S. Gragoudas

  3. The MD Anderson Cancer Center, Texas, USA

    Dan S. Gombos

  4. Retina Service, Massachusetts Eye and Ear, Harvard Medical School, Boston, USA

    Mary E. Aronow

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Ebrahimi, K.B., Hang, A., O’Brien, J.M. (2021). Current Management of Retinoblastoma. In: Albert, D., Miller, J., Azar, D., Young, L.H. (eds) Albert and Jakobiec's Principles and Practice of Ophthalmology. Springer, Cham. https://doi.org/10.1007/978-3-319-90495-5_268-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-90495-5_268-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-90495-5

  • Online ISBN: 978-3-319-90495-5

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation